



HEALTH POLICY DISCUSSION

**Follow-on Drug Development:
Wasteful Imitation or Productive Competition?**

Wednesday, December 15, 2004, 9:15–11:00 a.m.
Wohlstetter Conference Center, Twelfth Floor, AEI
1150 Seventeenth Street, N.W., Washington, D.C. 20036

Several recent books have criticized the pharmaceutical industry for developing too many “follow-on” or “me-too” drugs—a name given to drugs that work the same way as pioneering drugs that create a new class of treatments. Do follow-on drugs raise costs while diverting R&D funds from true innovation, and should the FDA raise the bar for approving follow-on drugs? Or are these drugs just competition at work, generating lower prices and better products? These and other questions will be addressed by a panel that will include a presentation by Joseph A. DiMasi—of the Tufts Center for the Study of Drug Development—who has just completed a new study with colleague Cherie Paquette on “The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development.” The study was recently published in PharmacoEconomics.

9:00 a.m. Registration

9:15 *Speaker:* JOSEPH A. DIMASI, Tufts University

Discussants: SCOTT GOTTLIEB, AEI
ALAN LYLES, University of Baltimore

Moderator: JOHN E. CALFEE, AEI

11:00 Adjournment

I will attend the health policy discussion on Wednesday, December 15.

Name: _____

Title: _____

Affiliation: _____

Address: _____

City/State/Zip: _____

Telephone: _____ Fax: _____

E-mail: _____

Please check if this is a new address.

Please register online at www.aei.org/events or by faxing this form to 202.862.7171. Shortly after the event occurs, a video webcast will be available on the AEI website at www.aei.org/eventvideos.

For more information, please contact Ximena Pinell at 202.862.7183 or xpinell@aei.org.

For media inquiries, please contact Veronique Rodman at vrodman@aei.org.